The Motley Fool

Admedus Ltd delivers another big loss

This morning regenerative medicine business Admedus Ltd (ASX: AHZ) reported its results for the year ending June 30, 2017. Below is a summary of the results with comparisons to the prior corresponding year.

  • Net loss of $12.7m, decrease of 50%
  • Revenues of $22.3m, up 58%
  • Net operating cash outflow of $12.5m, compared to $21.9m in prior year
  • Operating expenses reduced by $8.4m or 25%
  • Conducted a capital raising of $17.1m
  • Cash on hand of $11.3m

After a strategic review named “Code Red” the company has delivered improved financials on an FY 2016 that delivered cash outflows as high as $21.9 million. The group also highlighted the 30% growth in sales across its Adapt portfolio of regenerative medicine products focused on cardiac repair.

The company also has a profitable general medical equipment business named Infusion, while it is also investing heavily in a business that conducts clinical trials on treatments for a wide variety of common human conditions.

Admedus also forecast that it expects to “approach financial break even in the last quarter of calendar 2018 with the expectation of being profitable for the full calendar year 2019.” The stock is down 30% over the past year and the company will need to deliver a dramatic turnaround to deliver on management’s forecasts. Given its track record of consuming shareholder capital and delivering losses this is a stock I have repeatedly suggested investors avoid. And not for nothing either.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

*Returns as of June 30th

Tom Richardson has no interest in any security mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool has no interest in any company mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policyThis article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Related Articles...

Latest posts by Tom Richardson (see all)